Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Valproic acid
Drug ID BADD_D02329
Description Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton.[A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene.[L6190] Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types.
Indications and Usage For treatment and management of seizure disorders, mania, and prophylactic treatment of migraine headache. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome.
Marketing Status Prescription; Discontinued
ATC Code N03AG01
DrugBank ID DB00313
KEGG ID D00399
MeSH ID D014635
PubChem ID 3121
TTD Drug ID D03LGY
NDC Product Code 0591-4012; 17856-0152; 63629-2454; 72189-267; 60432-621; 0121-4675; 72189-010; 43353-085; 17349-0005; 68108-0203; 71930-057; 69452-150; 62756-920; 66064-8001; 17856-0675; 11014-0054; 0121-1350; 0615-8205; 68094-701; 43353-107; 10888-8132; 11014-0050; 70518-0079; 63739-253; 70518-0730; 42291-844; 0832-0310; 23639-0003; 50383-792; 68094-193; 0121-0675; 0527-5250; 49452-8092; 63739-086; 68925-0002; 43353-279; 63629-7597; 60687-262
Synonyms Valproic Acid | 2-Propylpentanoic Acid | 2 Propylpentanoic Acid | Divalproex | Depakene | Convulsofin | Depakote | Dipropyl Acetate | Divalproex Sodium | Semisodium Valproate | Vupral | Valproic Acid, Sodium Salt (2:1) | Propylisopropylacetic Acid | Ergenyl | Magnesium Valproate | Valproate | Valproate Sodium | Sodium Valproate | Calcium Valproate | Valproate Calcium | Depakine
Chemical Information
Molecular Formula C8H16O2
CAS Registry Number 99-66-1
SMILES CCCC(CCC)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionCytochrome P450 1A2P05177Not AvailableNot Available
HepatotoxicityCytochrome P450 2A6P11509T06455Not Available
HepatotoxicityCytochrome P450 2E1P05181Not AvailableNot Available
HepatotoxicityCytochrome P450 2C9P11712T19244Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.003--
Abdominal tenderness07.01.05.0040.001772%Not Available
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Abortion spontaneous18.01.04.0010.013729%Not Available
Acidosis14.01.03.0020.003322%
Acidosis hyperchloraemic14.01.01.0070.000443%Not Available
Acne23.02.01.001--Not Available
Activated partial thromboplastin time prolonged13.01.02.0010.000664%
Acute hepatic failure09.01.03.0010.001444%Not Available
Acute respiratory distress syndrome22.01.03.0010.000231%
Acute respiratory failure22.02.06.001; 14.01.04.004--Not Available
Administration site reaction12.07.04.011; 08.02.04.011--Not Available
Affective disorder19.04.04.0010.001772%Not Available
Aggression19.05.01.0010.007529%Not Available
Agitation19.06.02.001; 17.02.05.0120.006865%
Agranulocytosis01.02.03.001--Not Available
Akathisia19.06.02.006; 17.01.02.002--
Akinesia17.01.02.0030.001107%Not Available
Alanine aminotransferase increased13.03.01.0030.004429%
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.0010.002214%Not Available
Amblyopia06.02.01.0010.001107%Not Available
Amenorrhoea21.01.02.001; 05.05.01.002--
Ammonia increased13.03.01.0230.010186%Not Available
Amnesia19.20.01.001; 17.03.02.001--
Amylase increased13.05.01.0090.001329%
The 1th Page    1 2 3 4 5    Next   Last    Total 30 Pages